FSII

MCP Computer Products Celebrates 25th Anniversary as a Small Business Government Contractor

Retrieved on: 
Thursday, January 26, 2023
Federation, DELL, Small business, GSA, Government, Dell, FSII, SEWP, BPA, SAN, Government agency, MCP, V8, GSS, Music

SAN MARCOS, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- January 2023 marks the 25th anniversary of MCP Computer Products Inc., a growing certified Woman-Owned Small Business.

Key Points: 
  • SAN MARCOS, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- January 2023 marks the 25th anniversary of MCP Computer Products Inc., a growing certified Woman-Owned Small Business.
  • MCP was able to grow by engaging with local San Diego small business organizations and attending multiple small business workshops.
  • This resulted in a large government contractor awarding MCP Small Business of the year in 1999.
  • "We believe small business plays an integral part in helping the Government save money on IT purchases and distribution," said MCP CEO Rikki Ghai.

Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 29, 2022
Cell, Regulation, Foresite Capital, Safety, NASDAQ, Interim, Investor, COV, Pharmacokinetics, Coronavirus, Board, Public expenditure, IND, SPAC, Program, Subclinical infection, The Conference Board, DAA, CROI, Conference, PIPE, CEO, RNA, Severe acute respiratory syndrome coronavirus 2, Antiviral Research, Senior, ICAR, NCT, Regulation Fair Disclosure, Disclosure, COVID-19, U.S. Securities and Exchange Commission, GLOBE, NDA, Erik De Clercq, Infection, International Conference on Emerging Infectious Diseases, BID, FSII, FDA, Key, PRDS, Science, Acquisition, Security (finance), Pharmaceutical industry, Management, Cryptocurrency, Research, Pardes

Completed Business Combination with FS Development Corp. II: In December 2021, Pardes completed its business combination with FS Development Corp. II (FSII), a special purpose acquisition company (SPAC) sponsored by Foresite Capital.

Key Points: 
  • Completed Business Combination with FS Development Corp. II: In December 2021, Pardes completed its business combination with FS Development Corp. II (FSII), a special purpose acquisition company (SPAC) sponsored by Foresite Capital.
  • Strengthened Leadership Team with Key Additions: Pardes has grown its executive and senior leadership team with several key appointments across manufacturing, research, and business development.
  • Significant hires include:
    Valdas Jurkauskas, Ph.D.: Pardes appointed Valdas Jurkauskas as Senior Vice President of Technical Operations.
  • Accordingly, investors should monitor Pardes Biosciences Investors website, in addition to following Pardes press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

Retrieved on: 
Monday, December 27, 2021
U.S. Securities and Exchange Commission, Nasdaq, Movement, Patient, Pardes, Form, Drug discovery, FSII, Time, Coronavirus, DAA, Terminology, LLC, RA, Industry, Growth, White & Case, Acquisition, Forward-looking statement, SEC, Pandemic, COVID-19, SVB Leerink, LLP, Jefferies Group, Gilead Sciences, Foresite Capital, Trial of the century, USPTO, Severe acute respiratory syndrome coronavirus 2, GLOBE, Infection, PIPE, SPAC, Pharmaceutical industry, Security (finance)

Pardes Biosciences, Inc., the resulting combined company, will commence trading its shares Monday, December 27th on the Nasdaq Global Market under the symbol PRDS.

Key Points: 
  • Pardes Biosciences, Inc., the resulting combined company, will commence trading its shares Monday, December 27th on the Nasdaq Global Market under the symbol PRDS.
  • Pardes Biosciences management team will continue to be led by Chief Executive Officer Uri A. Lopatin, M.D.
  • We founded Pardes Biosciences in early 2020 to help solve pandemic-sized problems, starting with COVID-19, said Uri A. Lopatin, M.D., Chief Executive Officer of Pardes Biosciences.
  • Pardes Biosciences protease inhibitor, PBI-0451, is currently in Phase I clinical study with early results showing potential for an unboosted oral regimen against COVID-19.

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

Retrieved on: 
Tuesday, December 21, 2021
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hospital, Pfizer, Proxy, Business architecture, Drug discovery, Infection, Shareholder, Trial of the century, Intention, Virus, Death, Press release, Antibody, Diagnosis, Person, Public health, Failure, CEO, Form, Movement, Name, COVID-19, Vaccine, NASDAQ, Nasdaq, Hepatitis, FSII, Risk, Business, Securities Act of 1933, Pharmacokinetics, Severe acute respiratory syndrome coronavirus 2, Immunodeficiency, Forward-looking statement, Registration statement, U.S. Securities and Exchange Commission, Ritonavir, Coronavirus, COVID, Company, Suite, SEC, Delta, HIV, Human, Register, SEC filing, Sale, Omicron, Patient, Prospectus, Terminology, Foresite Capital, Chief executive officer, Pharmaceutical industry, San Francisco Bay Area, Pardes, Pardes Biosciences, Inc., PBI-0451, FS Development Corp. II (FSII), PARDES BIOSCIENCES, INC., PBI-0451, FS DEVELOPMENT CORP. II (FSII)

We look forward to a world where the COVID pandemic is defeated by a combination of outbreak surveillance, vaccines, and oral antivirals.

Key Points: 
  • We look forward to a world where the COVID pandemic is defeated by a combination of outbreak surveillance, vaccines, and oral antivirals.
  • Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19.
  • Pardes Biosciences is committed to innovating every aspect of how we work, including the flexibility of remote working and regional hubs.
  • PBI-0451 is being developed as a direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infection and associated diseases.

FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021

Retrieved on: 
Wednesday, December 1, 2021
Professional Services, Health, Other Professional Services, Other Science, Finance, Science, Biotechnology, Special, Sale, Securities Act of 1933, Date, Form S-4, Forward-looking statement, Company, Form, SEC, Proxy, SEC filing, Tripura Merger Agreement, Business, COVID-19, U.S. Securities and Exchange Commission, Prospectus, Nasdaq, Communication, Terminology, FSII, Business architecture, Person, Intention, Suite, Failure, Security (finance), Property management

FS Development Corp. II, a Delaware corporation (the Company) (Nasdaq: FSII), announced today that its registration statement on Form S-4 (File No.

Key Points: 
  • FS Development Corp. II, a Delaware corporation (the Company) (Nasdaq: FSII), announced today that its registration statement on Form S-4 (File No.
  • Notice of the Special Meeting is being mailed on December 1, 2021 to stockholders of record as of the Record Date.
  • The preliminary and definitive proxy statement/prospectus included in the registration statement can also be obtained, without charge, at the SECs website ( www.sec.gov ).
  • No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

Pardes Bioscience Announces Issuance of Its First U.S. Patent

Retrieved on: 
Tuesday, September 21, 2021
Patent, Securities Act of 1933, Form S-4, Suite, Tripura Merger Agreement, FSII, Infection, Pandemic, Person, Proxy, Intention, Sale, U.S. Securities and Exchange Commission, USPTO, IP, Form, GLOBE, Acquisition, Coronavirus, Terminology, Program, Foresite Capital, COVID-19, Severe acute respiratory syndrome coronavirus 2, Drug discovery, Forward-looking statement, Prospectus, Nasdaq, SEC, Pharmaceutical industry, Security (finance), Property management

CARLSBAD, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical--stage biopharmaceutical company,today announced that the U.S. Patent and Trademark Office has issued a new patent No.

Key Points: 
  • CARLSBAD, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical--stage biopharmaceutical company,today announced that the U.S. Patent and Trademark Office has issued a new patent No.
  • 11,124,497 (the 497 patent), strengthening the Companys intellectual property position for the Companys antiviral drug development program.
  • The 497 patent covers compounds designed to inhibit an essential viral protein, the main protease (Mpro) of SARS-CoV-2, the virus causing COVID-19.
  • Pardes Biosciences is a clinical-stage biopharmaceutical company committed to solving some of the worlds most pressing public health challenges.

Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections

Retrieved on: 
Thursday, August 26, 2021
Terminology, Securities Act of 1933, Severe acute respiratory syndrome coronavirus 2, Proxy, U.S. Securities and Exchange Commission, Form, Acquisition, GLOBE, Tripura Merger Agreement, Intention, Pharmacokinetics, SEC, Infection, Pandemic, Coronavirus, Drug discovery, Nasdaq, Person, Forward-looking statement, FSII, Prospectus, Safety, Form S-4, Disclosure, Suite, Sale, Foresite Capital, COVID-19, Pharmaceutical industry, Vaccine, Property management

This trial marks a significant milestone in our efforts to develop PBI-0451 as a potential oral antiviral therapy for SARS-CoV-2, and we look forward to providing updates on our progress.

Key Points: 
  • This trial marks a significant milestone in our efforts to develop PBI-0451 as a potential oral antiviral therapy for SARS-CoV-2, and we look forward to providing updates on our progress.
  • Pardes Biosciences is a clinical-stage biopharmaceutical company committed to solving some of the worlds most pressing public health challenges.
  • The companys lead product candidate, PBI-0451, is being developed as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.
  • Most of these factors are outside of FS Development Corp. IIs and Pardes control and are difficult to predict.